

[How It Works](#)[Team](#)[Investor Perks](#)[Market](#)[INVEST NOW](#)

BRINGING CRISPR TECHNOLOGY TO THE **\$150B PET** **MARKET**¹

Our team of genetics experts and industry veterans plans to use CRISPR technology to eliminate the genes that cause allergies in owners and diseases in our pets.

[INVEST NOW](#)

Deal Terms:

\$5.00Price per
Share**\$35M**

Valuation

\$1,000Min.
Investment[Offering Circular](#)[FORM C](#)[Investor Perks](#)[HOW IT WORKS](#)

[How It Works](#)[Team](#)[Investor Perks](#)[Market](#)

OUR GOAL IS TO MAKE PETS HEALTHIER

Our plan is to use CRISPR to modify disease-causing genes in pets, making pets healthier and helping them live longer.

We intend to target:



Genes that cause allergies in pet owners



Cancer-causing genes



Genes that cause hip dysplasia



Genes that cause cataracts

[INVEST NOW](#)[INVEST NOW](#)



AdoraPet

How It Works

Team

Investor Perks

Market

INVEST NOW



CRISPR is a natural process where bacteria use special enzymes to find and cut up the DNA of viruses. Scientists realized they could harness this process to edit any DNA strand, opening up the possibility of modifying the genes that causes diseases or repairing mutant DNA. The first scientists who discovered how to use CRISPR won the Nobel Prize.

TEAM

CO-FOUNDED BY
A TEAM OF
VISIONARIES



For a limited time, receive 20% bonus shares on top of your investment.



How It Works

Team

Investor Perks

Market



Dr. George Church
Co-Founder

Co-Founded by a
Gene

INVEST NOW

We're able to leverage world-class technology because of our world-class team. AdoraPet Co-Founder Dr. George Church is one of the world's leading pioneers of gene therapy.


INVEST NOW

One of the initiators of the
Human Genome Project

TIME Magazine's "100
Most Influential People in
the World"

Co-Founder of Colossal,
the company de-extincting
the woolly mammoth



[How It Works](#)[Team](#)[Investor Perks](#)[Market](#)[INVEST NOW](#)

Dr. Richard Chin

- Founder and CEO of KindredBio (NASDAQ:KIN), pet company that was sold for \$440M
- Harvard MD and Rhodes Scholar
- Developed drugs with over \$10B of global sales in 2021



Dr. Stephen Sundlof

- Former head of the FDA's Center for Veterinary Medicine
- Oversaw FDA regulatory oversight of glow-in-the-dark pet fish
- Former Chief Scientific Officer of KindredBio



For a limited time, receive 20% bonus shares on top of your investment.



INVEST NOW

*Note: Investor perks do not stack.

MARKET SIZE

For a limited time, receive 20% bonus shares on top of your investment.



[How It Works](#)

[Team](#)

[Investor Perks](#)

[Market](#)

[INVEST NOW](#)

THE PET MARKET CONTINUES TO GROW

We believe people will do just about anything for their pets, including paying a premium for a pet that meets their needs. After all, 95% of pet owners consider their pets part of their family.



**OVER 6 MILLION CATS
AND DOGS ENTER
SHELTERS EVERY YEAR³**



**11% OF CATS ARE
SURRENDERED BECAUSE
THEIR OWNERS HAVE
ALLERGIES⁴**



**U.S. PET MARKET SALES
HAVE GROWN 100% IN
THE LAST DECADE⁵**





[How It Works](#)

[Team](#)

[Investor Perks](#)

[Market](#)


[INVEST NOW](#)

OUR PATH FORWARD

BRINGING ADORAPET TO MARKET

This funding round will help support our mission to bring healthier, longer-living pets to more homes. We plan to use these funds for research & development including: establishing our laboratory and breeding facilities, and other operational costs.

[INVEST NOW](#)






Loading Comments

© 2022 Adora Pet

 [Facebook](#)

 [Instagram](#)

 (415) 371-9844

 investor.relations@adora.pet

1. The global pet care market size was valued at USD 150.67 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 5.1% from 2022 to 2030. **Source.**

2. Each person who qualifies for a "Company Perk" will be assigned a spot in line in their respective tier. Once the allotment for each tier is exhausted, there will be no more company perk for that tier this round. The company perks are transferrable and apply to the first animals that are commercialized to the public. Not applicable to those sold to breeders as breeding stock, those provided free of charge, or those used for clinical studies. The perk is not for the animal itself but for the spot in line. Investors who satisfy the criteria for each tier are still required to pay for their AdoraPet animal.

3. Over 6 million cats and dogs enter shelters every year. **Source.**

4. 11% of cats are surrendered because their owners have allergies. **Source.**

5. U.S. pet sales have grown 100% in the last decade. **Source.**

For a limited time, receive 20% bonus shares on top of your investment.

can not afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, commercial or tested in the public marketplace. The stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid securities that may be subject to holding period requirements and/or liquidity concerns.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 105 Maxess Road, Suite 124, Melville, NY 11747, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's **BrokerCheck**.

DealMaker Securities LLC does not make investment recommendations.

DealMaker Securities LLC is **NOT** placing or selling these securities on behalf of the Issuer.

DealMaker Securities LLC is **NOT** soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.

DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.

DealMaker Securities LLC is **NOT** vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor's submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.



How It Works

Team

Investor Perks

Market

INVEST NOW